Verici Dx has opened up a new commercial opportunity by becoming an Olink Certified Service Provider, allowing its US laboratory to offer proteomics services to pharmaceutical, biotech and other life-science customers. The move gives Verici Dx an additional fee-for-service revenue stream alongside its kidney-transplant diagnostics business and should also help improve utilisation of its existing laboratory infrastructure.
Its new contract research offering can be used for biomarker discovery, algorithm development, validation, clinical trials and diagnostic development. That broadens the range of work the company can undertake without moving far from its existing expertise in multi-omic data, biomarkers and precision medicine.
Verici Dx has already shown that the capability can attract commercial work. The company has analysed samples from a GLP-1 clinical trial for a major pharmaceutical customer using a custom protein panel. That is important because the service is not simply a new theoretical capability. It has already been applied to a live pharmaceutical project.
The certification also fits with Verici Dx’s core positioning. Its kidney-transplant diagnostics use multi-omic data and artificial intelligence to help clinicians assess the risk of organ rejection and tailor immunosuppression. Adding proteomics services gives the company another way to monetise the laboratory, technical expertise and biomarker capabilities it has already built.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
